Investors Think This Company's Gut Bacteria Are Worth $1.9 Billion
Wall Street loves feces—or at least the promise that it will one day yield new medical treatments.
Shares of Seres Therapeutics, a company trying to create new medicines from the bacteria in the human gut, nearly tripled in their first day of trading on Friday, giving the company a first-day market cap of $1.9 billion.
Hey, check out all the research scientist jobs. Post your resume today!
Shares of Seres Therapeutics, a company trying to create new medicines from the bacteria in the human gut, nearly tripled in their first day of trading on Friday, giving the company a first-day market cap of $1.9 billion.
Hey, check out all the research scientist jobs. Post your resume today!